Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics, Inc. (ARQT) is a healthcare company (biotechnology) based in the United States. The share price is $27.33, up 0.66% on the day, which values the company at $3.46B. Price as of 18 Nov 2026, 10:10 UTC, from Yahoo Finance.

Key facts

Share price
$27.33+0.66% today
Market value
$3.46B
P/E ratio
124.2×last 12 months
Forward P/E
25.0×
Funk Score
45/100
Against its own history
Well above its usual priceusual price $16.42
200-week average
$15.0582% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Arcutis Biotherapeutics, Inc. in more detail

ARQT trades at 124.2× its last twelve months' earnings, 25.0× next year's expected earnings, 6.8× sales. Measured against its own history, the price is 66% above what its usual multiples would imply ($16.42) — well above its usual price. It sits 82% above its 200-week average of $15.05.

Its Funk Score is 45 out of 100 (financial strength 6.1, profitability 2.0, growth 10.0, value 0.0, each out of 10).

In its favour: Altman Z in the safe zone; Operating margin is expanding. Worth checking: Beneish M-score flags the accounts; Share count keeps rising.

Arcutis Biotherapeutics, Inc. (ARQT): questions and answers

What is ARQT's P/E ratio?

Arcutis Biotherapeutics, Inc. trades at 124.2× its last twelve months' earnings and 25.0× next year's expected earnings.

What is Arcutis Biotherapeutics, Inc.'s market cap?

Arcutis Biotherapeutics, Inc. is valued at $3.46B at a share price of $27.33.

Is ARQT overvalued or undervalued?

Against its own history, ARQT is well above its usual price: the price is 66% above the $16.42 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is ARQT above its 200-week moving average?

Yes. ARQT is 81.5% above its 200-week average of $15.05. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Arcutis Biotherapeutics, Inc. growing?

Over the last three fiscal years Arcutis Biotherapeutics, Inc.'s revenue grew 367.3% a year.

Does ARQT pay a dividend?

Arcutis Biotherapeutics, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Arcutis Biotherapeutics, Inc. (ARQT) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/ARQT

Underlying data: Yahoo Finance; company filings with the SEC.